Skip to main content

EURopean Endeavour for Chimeric Antigen Receptor Therapies

Objective

Cancer is rapidly becoming the most frequent cause of death in EU. Though enormously expensive (several billions EUR/year), currently available anti-cancer therapies are major causes of chronic diseases. Adoptive immunotherapy with T cells genetically modified with a tumour-reactive chimeric antigen receptor (CAR) is an innovative therapeutic concept, promising to eradicate cancer without causing secondary chronic diseases. This approach is already at an advanced stage of development in the US, but struggles in the EU, due to a number of constrains that will be specifically tackled by this Project. The ultimate goal of EURE-CART is to bring EU at the forefront CAR T-cell immunotherapy. In this Project, we will extend the applicability of CAR T-cell immunotherapy to incurable tumours that have never been tackled with this approach. The EURE-CART Consortium is composed of 6 academic centres, 2 SMEs and 1 large enterprise from 6 EU countries, clearly representing excellences in their respective fields. EURE-CART will bring together clinical experts in oncology, and pioneers and leaders in the field of cell and gene therapy for conducting a first-in-man Phase I/II clinical trial. To be successful, EURE-CART proposes the early involvement of National regulatory authorities for accelerating the approval of CAR T-cell immunotherapy, as well as the centralisation of its production by the Molmed Spa. Molmed Spa is uniquely endowed in the EU with the know-how and experience necessary to meet this ambitious objective, as demonstrated by its unparalleled track record. The main expected impact of EURE-CART is the establishment of CAR T-cell therapy as the ultimate personalised therapy, capable of defeating chronic diseases, and to create secure new jobs in the EU through the instalment of an unprecedented alliance between academia, industry and regulatory bodies.

Field of science

  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug
  • /medical and health sciences/clinical medicine/cancer/skin cancer/squamous cell carcinoma
  • /medical and health sciences/clinical medicine/cancer/leukemia
  • /medical and health sciences/basic medicine/immunology/immunotherapy
  • /medical and health sciences/medical biotechnology/genetic engineering/gene therapy
  • /medical and health sciences/medical biotechnology/cells technologies

Call for proposal

H2020-SC1-2016-RTD
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

MOLECULAR MEDICINE SPA
Address
Via Olgettina 58
20132 Milano
Italy
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 1 994 575

Participants (9)

OSPEDALE SAN RAFFAELE SRL
Italy
EU contribution
€ 1 112 500
Address
Via Olgettina 60
20132 Milano
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT
Germany
EU contribution
€ 856 076,25
Address
Josef-schneider-strasse 2
97080 Wurzburg
Activity type
Higher or Secondary Education Establishments
OSPEDALE PEDIATRICO BAMBINO GESU
Italy
EU contribution
€ 492 431,25
Address
Piazza Sant Onofrio 4
00165 Roma
Activity type
Other
INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU FUNDACION
Spain
EU contribution
€ 225 011
Address
C Sant Quinti 77-79
08041 Barcelona
Activity type
Research Organisations
FAKULTNI NEMOCNICE OSTRAVA
Czechia
EU contribution
€ 224 552,50
Address
17 Listopadu 1790
708 52 Ostrava Poruba
Activity type
Research Organisations
ISTITUTO SUPERIORE DI SANITA
Italy
EU contribution
€ 225 000
Address
Viale Regina Elena 299
00161 Roma
Activity type
Research Organisations
ACROMION GMBH
Germany
EU contribution
€ 398 000
Address
Europaallee 27-29
50226 Frechen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ARTTIC
France
EU contribution
€ 325 912,10
Address
Rue Du Dessous Des Berges 58A
75013 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ARTTIC INNOVATION GMBH
Germany
EU contribution
€ 49 087,90
Address
Oskar-von-miller-ring 29
80333 Munchen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)